Current therapeutic strategies for hepatocellular carcinoma (HCC) primarily rely on multi-targeted small molecule agents and immune checkpoint inhibitors. However, clinical trials have demonstrated limited efficacy of erlotinib monotherapy and its combination ... ...

请注册登录后继续浏览